Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
Table 3
Resistance-associated mutations in reverse transcriptase at week 8 after interruption of NNRTI-based ART, according to the interruption modality, HIV-1 RNA load at interruption, and NNRTI concentrations at week 4 post-interruption.